Auryxia

Hyperphosphataemia, Dialysis therapy, Iron Deficiency Anemia + 2 more
Treatment
7 FDA approvals
20 Active Studies for Auryxia

What is Auryxia

Tetraferric tricitrate decahydrateThe Generic name of this drug
Treatment SummaryTetraferric tricitrate decahydrate is a medication used to treat high levels of phosphates in the blood and iron deficiency anemia, both of which are seen in adults with chronic kidney disease. The drug was approved by the FDA in 2014 and is also known under the brand name Triferic.
Auryxiais the brand name
Auryxia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Auryxia
Tetraferric tricitrate decahydrate
2014
1

Approved as Treatment by the FDA

Tetraferric tricitrate decahydrate, also known as Auryxia, is approved by the FDA for 7 uses including Iron Deficiency Anemia (IDA) and Chronic Kidney Disease (CKD) .
Iron Deficiency Anemia (IDA)
Chronic Kidney Disease (CKD)
Iron Deficiency Anemia
Not on Dialysis
Dialysis therapy
Chronic Kidney Disease
Hyperphosphataemia

Effectiveness

How Auryxia Affects PatientsTetraferric tricitrate decahydrate is a medicine that contains iron and is used to treat iron deficiency anemia and high levels of phosphate in the blood. The dose can vary from person to person, but it works for a long time to treat anemia and a moderate amount of time to treat hyperphosphatemia. Patients should be aware of the potential risks associated with iron overload when taking this medication.
How Auryxia works in the bodyFerric iron is taken in from the digestive system and changed into ferrous iron. This ferrous iron is stored in the cells and then moved into the blood by a protein called ferroportin 1. In the blood, it binds to transferrin, which carries it to other cells. These cells use the iron to make hemoglobin and other proteins. Some of the ferric iron binds to phosphate in the digestive system, forming an insoluble substance that cannot be absorbed. This substance is then eliminated in the feces, reducing phosphate levels in the blood.

When to interrupt dosage

The recommended measure of Auryxia hinges upon the diagnosed issue, including Not on Dialysis, Dialysis therapy and Chronic Kidney Disease. Dosage is also contingent upon the technique of administration specified in the table below.
Condition
Dosage
Administration
Hyperphosphataemia
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Dialysis therapy
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Iron Deficiency Anemia
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Chronic Kidney Disease
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Not on Dialysis
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Auryxia has one contraindication, and should thus not be administered with any of the conditions mentioned in the following table.Auryxia Contraindications
Condition
Risk Level
Notes
Iron Overload
Do Not Combine
There are 20 known major drug interactions with Auryxia.
Common Auryxia Drug Interactions
Drug Name
Risk Level
Description
Technetium Tc-99m oxidronate
Major
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Phosphate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dipotassium phosphate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Auryxia Toxicity & Overdose RiskOverdosing on iron can cause nausea, vomiting, abdominal pain, diarrhea, blood loss, low blood pressure, throwing up blood, perforation, and infection of the abdomen. Mild overdoses can be treated with supportive care, while more severe cases may require chelation therapy or IV fluids. Taking activated charcoal is not likely to help in iron overdose. The lowest toxic dose of iron in rats has been found to be 1487mg/kg in rats and 1520mg/kg in mice.
image of a doctor in a lab doing drug, clinical research

Auryxia Novel Uses: Which Conditions Have a Clinical Trial Featuring Auryxia?

121 active clinical trials are exploring the potential of Auryxia to aid in managing Chronic Kidney Disease, Iron deficiency anemia and Non-Dialysis patients.
Condition
Clinical Trials
Trial Phases
Dialysis therapy
4 Actively Recruiting
Not Applicable, Phase 3, Phase 4
Hyperphosphataemia
0 Actively Recruiting
Chronic Kidney Disease
101 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Iron Deficiency Anemia
7 Actively Recruiting
Phase 3, Phase 4, Phase 2, Not Applicable
Not on Dialysis
0 Actively Recruiting

Auryxia Reviews: What are patients saying about Auryxia?

5Patient Review
9/2/2015
Auryxia for Renal Osteodystrophy with Hyperphosphatemia
5Patient Review
9/4/2015
Auryxia for Renal Osteodystrophy with Hyperphosphatemia
5Patient Review
2/19/2016
Auryxia for Renal Osteodystrophy with Hyperphosphatemia
4.3Patient Review
10/4/2018
Auryxia for Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
I'm kept getting yeast infections since starting this medication, and I wonder if it's because of the Auryxia. That said, my Hgb and Hct levels have increased, so there are some definite positives to taking this medicine even though it's quite expensive.
3.7Patient Review
8/15/2017
Auryxia for Renal Osteodystrophy with Hyperphosphatemia
I wasn't able to get my phosphorous levels under control, even with the lapband. The pills were too big and I had to have it loosened. Within a few months, my level went from 11.5 to 6.
3Patient Review
4/28/2016
Auryxia for Renal Osteodystrophy with Hyperphosphatemia
I'm a bit hesitant to keep taking this medication for an extended period of time because of the potential liver damage. Additionally, I was not pleased with the change in stool color.
1Patient Review
8/14/2016
Auryxia for Renal Osteodystrophy with Hyperphosphatemia
I no longer needed regular iron infusions thanks to this medication. Not only that, but my constipation became less chronic and I had fewer stomach upsets. However, I started getting itchy skin and eyes so I'm going to take a break from Aryuxia for now.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about auryxia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Auryxia tablet?

"Auryxia can lower the amount of phosphate in the blood for adults with chronic kidney disease who are on dialysis."

Answered by AI

Is Auryxia a generic or brand?

"There is not currently a version of Auryxia that is the same as what is available in the United States. There may be illegal online pharmacies that sell a generic version of Auryxia, but these medications may not be safe."

Answered by AI

What are side effects of Auryxia?

"Auryxia may cause common side effects such as diarrhea, constipation, darker color in your bowel movements, nausea, vomiting, stomach pain, or cough."

Answered by AI

What is Auryxia used for?

"This medication works by binding to phosphate in the foods you eat, which then passes out of your body in your stool. Ferric citrate is a form of iron that is also used to treat low blood levels of iron (anemia) in people with long-term kidney disease who are not on dialysis."

Answered by AI

Clinical Trials for Auryxia

Image of Trinity Research Group in Dothan, United States.

Velocity pAVF System for Kidney Failure

18 - 80
All Sexes
Dothan, AL
This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used. The Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis. The study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years. Taking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.
Recruiting
Has No Placebo
Trinity Research Group (+6 Sites)Venova Medical
Image of London Health Sciences Centre in London, Canada.

Exercise for Dialysis

18 - 79
All Sexes
London, Canada
Patients receiving regular hemodialysis (HD) treatments are at a higher risk of cardiovascular events and death as HD can cause a decrease in the pumping of the heart during treatment called 'stunning'. Intradialytic exercise has emerged as a safe and effective non-drug approach to improve cardiovascular health and is now recommended for patients undergoing HD. It is currently advised that HD patients engage in at least 30 minutes of moderate to vigorous exercise three times per week. This study will evaluate the impact of exercise intensity in the HD population and determine if high impact exercise can offer better protection to the heart against HD-induced myocardial stunning.
Recruiting
Has No Placebo
London Health Sciences CentreChris McIntyre, MBBS DM
Image of University of Alabama at Birmingham in Birmingham, United States.

Empagliflozin for Chronic Kidney Disease

2 - 17
All Sexes
Birmingham, AL
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD. Participants are put into 2 groups randomly, which means by chance. One group takes empagliflozin and the other group takes placebo. Placebo looks like empagliflozin but does not contain any medicine. Participants are twice as likely to be in the empagliflozin group. Participants take empagliflozin or placebo as tablets once a day for 6 months. After 6 months, participants in both groups take empagliflozin as tablets once a day for 1 year. Participants are in the study for a little over a year and a half. During this time, they visit the study site about 15 times and get at least 5 phone or video calls from the site staff. At the visits, the doctors take blood and urine samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.
Phase 3
Waitlist Available
University of Alabama at Birmingham (+33 Sites)Boehringer Ingelheim
Have you considered Auryxia clinical trials? We made a collection of clinical trials featuring Auryxia, we think they might fit your search criteria.Go to Trials
Image of Centre hospitalier affilié universitaire régional de Trois-Rivières in Trois-Rivières, Canada.

Endoscopic Evaluation for Iron-Deficiency Anemia

18 - 90
All Sexes
Trois-Rivières, Canada
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB). Participants will be randomized to either repeated endoscopic evaluations or a conservative medical approach with limited testing. The study aims to assess whether conservative management yields similar clinical outcomes and quality of life compared to standard repeated endoscopic procedures. Results will inform the design of a larger trial and address the current lack of guidelines for managing recurrent iron-deficiency anemia in this patient population.
Recruiting
Has No Placebo
Centre hospitalier affilié universitaire régional de Trois-RivièresÉva Mathieu, PhD
Have you considered Auryxia clinical trials? We made a collection of clinical trials featuring Auryxia, we think they might fit your search criteria.Go to Trials
Image of Rocky Mountain Kidney Care - Lone Tree in Lone Tree, United States.

AP301 for High Phosphate Levels

Any Age
All Sexes
Lone Tree, CO
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.
Phase 3
Recruiting
Rocky Mountain Kidney Care - Lone Tree (+18 Sites)Alebund Pharmaceuticals
Image of Focus Clinical Research in West Hills, United States.

Vicadrostat + Empagliflozin for Chronic Kidney Disease

18+
All Sexes
West Hills, CA
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease. In this study, participants are randomly assigned to one of two groups. Participants have an equal chance of being assigned to either group. In one group, participants take the 2 study medicines, vicadrostat and empagliflozin, every day for 3 months. In the other group, participants take placebo and empagliflozin for the first 1.5 months, and then they take vicadrostat and empagliflozin together for the next 1.5 months. The study medicines are taken orally as tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants are in the study for about 4.5 months. During this time, they visit the study site multiple times. Doctors regularly test kidney function by measuring specific proteins in the blood and urine. The results are compared between the two groups to see whether there are differences between starting the study medicines at the same time or one after the other. The doctors also regularly check participants' health and take note of any unwanted effects.
Phase 2
Recruiting
Focus Clinical Research (+20 Sites)Boehringer Ingelheim
Image of Foothills Medical Centre in Calgary, Canada.

Decision Aid for Chronic Kidney Disease and Coronary Artery Disease

18+
All Sexes
Calgary, Canada
Many people with kidney disease also have heart disease. The procedures used to diagnose and treat heart disease (e.g., angiograms, angioplasty, or surgery) can improve symptoms and cardiovascular outcomes, but pose greater risks of kidney complications for people with chronic kidney disease. It's therefore important that patients with kidney disease and their health care providers understand the benefits versus risks of these procedures and use that information to make informed decisions regarding their health care. Prior research done with patients with kidney disease and their health care providers has led to the develop of a decision aid designed to help doctors provide personalized information on the benefits versus risks of having a heart procedure, as well as help patients communicate their own values and preferences to their doctor. This information is crucial for shared decision making, as previous research has shown that preferences and values vary for individual patients with kidney diseases, and should be incorporated into the decision-making process for heart disease management. The decision aid, called "My Heart Care and CKD", supports shared decision-making between patients with kidney disease and heart their care providers. This trial will implement and evaluate this decision aid within cardiovascular care in a pilot trial in Canada.
Waitlist Available
Has No Placebo
Foothills Medical Centre (+1 Sites)Matthew T James, MD
Have you considered Auryxia clinical trials? We made a collection of clinical trials featuring Auryxia, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security